The global Automated Molecular Diagnostics Testing System market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Automated Molecular Diagnostics Testing System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Automated Molecular Diagnostics Testing System.
Report Scope
The Automated Molecular Diagnostics Testing System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Automated Molecular Diagnostics Testing System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Automated Molecular Diagnostics Testing System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Roche Holding AG
Abbott Laboratories
Becton Dickenson & Company
Siemens Healthcare GmbH
Enigma Diagnostics Ltd
Qiagen
Bio-Rad Laboratories
Cepheid Inc.
PerkinElmer Inc.
AutoGenomics
ELITech Group
Segment by Type
PCR (Polymerase Chain Reaction)
FISH (Fluorescent In-situ Hybridization)
Spectral Karyotype Imaging
DNA Microarrays
Segment by Application
Pathology Laboratories
Hospitals
Research Centers
Academic Institutions
Commercial R&D Centers
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Automated Molecular Diagnostics Testing System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Automated Molecular Diagnostics Testing System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Automated Molecular Diagnostics Testing System 麻豆原创 Overview
1.1 Product Overview and Scope of Automated Molecular Diagnostics Testing System
1.2 Automated Molecular Diagnostics Testing System Segment by Type
1.2.1 Global Automated Molecular Diagnostics Testing System 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 PCR (Polymerase Chain Reaction)
1.2.3 FISH (Fluorescent In-situ Hybridization)
1.2.4 Spectral Karyotype Imaging
1.2.5 DNA Microarrays
1.3 Automated Molecular Diagnostics Testing System Segment by Application
1.3.1 Global Automated Molecular Diagnostics Testing System 麻豆原创 Value by Application: (2024-2030)
1.3.2 Pathology Laboratories
1.3.3 Hospitals
1.3.4 Research Centers
1.3.5 Academic Institutions
1.3.6 Commercial R&D Centers
1.4 Global Automated Molecular Diagnostics Testing System 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Automated Molecular Diagnostics Testing System Revenue 2019-2030
1.4.2 Global Automated Molecular Diagnostics Testing System Sales 2019-2030
1.4.3 Global Automated Molecular Diagnostics Testing System 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Automated Molecular Diagnostics Testing System 麻豆原创 Competition by Manufacturers
2.1 Global Automated Molecular Diagnostics Testing System Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Automated Molecular Diagnostics Testing System Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Automated Molecular Diagnostics Testing System Average Price by Manufacturers (2019-2024)
2.4 Global Automated Molecular Diagnostics Testing System Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Automated Molecular Diagnostics Testing System, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Automated Molecular Diagnostics Testing System, Product Type & Application
2.7 Automated Molecular Diagnostics Testing System 麻豆原创 Competitive Situation and Trends
2.7.1 Automated Molecular Diagnostics Testing System 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Automated Molecular Diagnostics Testing System Players 麻豆原创 Share by Revenue
2.7.3 Global Automated Molecular Diagnostics Testing System 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Automated Molecular Diagnostics Testing System Retrospective 麻豆原创 Scenario by Region
3.1 Global Automated Molecular Diagnostics Testing System 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Automated Molecular Diagnostics Testing System Global Automated Molecular Diagnostics Testing System Sales by Region: 2019-2030
3.2.1 Global Automated Molecular Diagnostics Testing System Sales by Region: 2019-2024
3.2.2 Global Automated Molecular Diagnostics Testing System Sales by Region: 2025-2030
3.3 Global Automated Molecular Diagnostics Testing System Global Automated Molecular Diagnostics Testing System Revenue by Region: 2019-2030
3.3.1 Global Automated Molecular Diagnostics Testing System Revenue by Region: 2019-2024
3.3.2 Global Automated Molecular Diagnostics Testing System Revenue by Region: 2025-2030
3.4 North America Automated Molecular Diagnostics Testing System 麻豆原创 Facts & Figures by Country
3.4.1 North America Automated Molecular Diagnostics Testing System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Automated Molecular Diagnostics Testing System Sales by Country (2019-2030)
3.4.3 North America Automated Molecular Diagnostics Testing System Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Automated Molecular Diagnostics Testing System 麻豆原创 Facts & Figures by Country
3.5.1 Europe Automated Molecular Diagnostics Testing System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Automated Molecular Diagnostics Testing System Sales by Country (2019-2030)
3.5.3 Europe Automated Molecular Diagnostics Testing System Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Automated Molecular Diagnostics Testing System 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Automated Molecular Diagnostics Testing System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Automated Molecular Diagnostics Testing System Sales by Country (2019-2030)
3.6.3 Asia Pacific Automated Molecular Diagnostics Testing System Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Automated Molecular Diagnostics Testing System 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Automated Molecular Diagnostics Testing System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Automated Molecular Diagnostics Testing System Sales by Country (2019-2030)
3.7.3 Latin America Automated Molecular Diagnostics Testing System Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Automated Molecular Diagnostics Testing System 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Automated Molecular Diagnostics Testing System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Automated Molecular Diagnostics Testing System Sales by Country (2019-2030)
3.8.3 Middle East and Africa Automated Molecular Diagnostics Testing System Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Automated Molecular Diagnostics Testing System Sales by Type (2019-2030)
4.1.1 Global Automated Molecular Diagnostics Testing System Sales by Type (2019-2024)
4.1.2 Global Automated Molecular Diagnostics Testing System Sales by Type (2025-2030)
4.1.3 Global Automated Molecular Diagnostics Testing System Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Automated Molecular Diagnostics Testing System Revenue by Type (2019-2030)
4.2.1 Global Automated Molecular Diagnostics Testing System Revenue by Type (2019-2024)
4.2.2 Global Automated Molecular Diagnostics Testing System Revenue by Type (2025-2030)
4.2.3 Global Automated Molecular Diagnostics Testing System Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Automated Molecular Diagnostics Testing System Price by Type (2019-2030)
5 Segment by Application
5.1 Global Automated Molecular Diagnostics Testing System Sales by Application (2019-2030)
5.1.1 Global Automated Molecular Diagnostics Testing System Sales by Application (2019-2024)
5.1.2 Global Automated Molecular Diagnostics Testing System Sales by Application (2025-2030)
5.1.3 Global Automated Molecular Diagnostics Testing System Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Automated Molecular Diagnostics Testing System Revenue by Application (2019-2030)
5.2.1 Global Automated Molecular Diagnostics Testing System Revenue by Application (2019-2024)
5.2.2 Global Automated Molecular Diagnostics Testing System Revenue by Application (2025-2030)
5.2.3 Global Automated Molecular Diagnostics Testing System Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Automated Molecular Diagnostics Testing System Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche Holding AG
6.1.1 Roche Holding AG Corporation Information
6.1.2 Roche Holding AG Description and Business Overview
6.1.3 Roche Holding AG Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Holding AG Automated Molecular Diagnostics Testing System Product Portfolio
6.1.5 Roche Holding AG Recent Developments/Updates
6.2 Abbott Laboratories
6.2.1 Abbott Laboratories Corporation Information
6.2.2 Abbott Laboratories Description and Business Overview
6.2.3 Abbott Laboratories Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Abbott Laboratories Automated Molecular Diagnostics Testing System Product Portfolio
6.2.5 Abbott Laboratories Recent Developments/Updates
6.3 Becton Dickenson & Company
6.3.1 Becton Dickenson & Company Corporation Information
6.3.2 Becton Dickenson & Company Description and Business Overview
6.3.3 Becton Dickenson & Company Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Becton Dickenson & Company Automated Molecular Diagnostics Testing System Product Portfolio
6.3.5 Becton Dickenson & Company Recent Developments/Updates
6.4 Siemens Healthcare GmbH
6.4.1 Siemens Healthcare GmbH Corporation Information
6.4.2 Siemens Healthcare GmbH Description and Business Overview
6.4.3 Siemens Healthcare GmbH Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Siemens Healthcare GmbH Automated Molecular Diagnostics Testing System Product Portfolio
6.4.5 Siemens Healthcare GmbH Recent Developments/Updates
6.5 Enigma Diagnostics Ltd
6.5.1 Enigma Diagnostics Ltd Corporation Information
6.5.2 Enigma Diagnostics Ltd Description and Business Overview
6.5.3 Enigma Diagnostics Ltd Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Enigma Diagnostics Ltd Automated Molecular Diagnostics Testing System Product Portfolio
6.5.5 Enigma Diagnostics Ltd Recent Developments/Updates
6.6 Qiagen
6.6.1 Qiagen Corporation Information
6.6.2 Qiagen Description and Business Overview
6.6.3 Qiagen Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Qiagen Automated Molecular Diagnostics Testing System Product Portfolio
6.6.5 Qiagen Recent Developments/Updates
6.7 Bio-Rad Laboratories
6.6.1 Bio-Rad Laboratories Corporation Information
6.6.2 Bio-Rad Laboratories Description and Business Overview
6.6.3 Bio-Rad Laboratories Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bio-Rad Laboratories Automated Molecular Diagnostics Testing System Product Portfolio
6.7.5 Bio-Rad Laboratories Recent Developments/Updates
6.8 Cepheid Inc.
6.8.1 Cepheid Inc. Corporation Information
6.8.2 Cepheid Inc. Description and Business Overview
6.8.3 Cepheid Inc. Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Cepheid Inc. Automated Molecular Diagnostics Testing System Product Portfolio
6.8.5 Cepheid Inc. Recent Developments/Updates
6.9 PerkinElmer Inc.
6.9.1 PerkinElmer Inc. Corporation Information
6.9.2 PerkinElmer Inc. Description and Business Overview
6.9.3 PerkinElmer Inc. Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.9.4 PerkinElmer Inc. Automated Molecular Diagnostics Testing System Product Portfolio
6.9.5 PerkinElmer Inc. Recent Developments/Updates
6.10 AutoGenomics
6.10.1 AutoGenomics Corporation Information
6.10.2 AutoGenomics Description and Business Overview
6.10.3 AutoGenomics Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AutoGenomics Automated Molecular Diagnostics Testing System Product Portfolio
6.10.5 AutoGenomics Recent Developments/Updates
6.11 ELITech Group
6.11.1 ELITech Group Corporation Information
6.11.2 ELITech Group Automated Molecular Diagnostics Testing System Description and Business Overview
6.11.3 ELITech Group Automated Molecular Diagnostics Testing System Sales, Revenue and Gross Margin (2019-2024)
6.11.4 ELITech Group Automated Molecular Diagnostics Testing System Product Portfolio
6.11.5 ELITech Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Automated Molecular Diagnostics Testing System Industry Chain Analysis
7.2 Automated Molecular Diagnostics Testing System Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Automated Molecular Diagnostics Testing System Production Mode & Process
7.4 Automated Molecular Diagnostics Testing System Sales and 麻豆原创ing
7.4.1 Automated Molecular Diagnostics Testing System Sales Channels
7.4.2 Automated Molecular Diagnostics Testing System Distributors
7.5 Automated Molecular Diagnostics Testing System Customers
8 Automated Molecular Diagnostics Testing System 麻豆原创 Dynamics
8.1 Automated Molecular Diagnostics Testing System Industry Trends
8.2 Automated Molecular Diagnostics Testing System 麻豆原创 Drivers
8.3 Automated Molecular Diagnostics Testing System 麻豆原创 Challenges
8.4 Automated Molecular Diagnostics Testing System 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Roche Holding AG
Abbott Laboratories
Becton Dickenson & Company
Siemens Healthcare GmbH
Enigma Diagnostics Ltd
Qiagen
Bio-Rad Laboratories
Cepheid Inc.
PerkinElmer Inc.
AutoGenomics
ELITech Group
听
听
*If Applicable.
